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Abstract: The enantioselective oxyfunctionalisation
of CH bonds is a highly interesting reaction, as it
provides access to chiral alcohols that are important
pharmaceutical building blocks. However, it is hard
to achieve using traditional methods. One way in
which it can be achieved is through the action of
oxidative enzymes. Although many reports of the
oxyfunctionalisation capabilities of enzymes at an
analytical scale have been published, reports on the
use of enzymes to achieve oxyfunctionalisation on a
synthetically relevant scale are fewer. Here, we
describe the scale-up of the conversion of 4-ethyl-
phenol to (R)-1-(4’-hydroxyphenyl)ethanol using
the flavin-dependent enzyme vanillyl alcohol
oxidase. The process was optimised by testing
different reaction media and substrate and enzyme
concentrations and by performing it under an
oxygen atmosphere. Under optimised reaction con-
ditions, 4.10 g (R)-1-(4’-hydroxyphenyl)ethanol at
97% ee was obtained from 10 g 4-ethylphenol
(isolated yield 36%). These results highlight some
of the challenges that can be encountered during
scale-up of an enzymatic oxyfunctionalisation proc-
ess to a synthetically relevant scale and will be of
use for the development of enzymatic processes for
the synthesis of industrially relevant compounds.
Keywords: Alcohols; Alkylphenols; Enantioselec-
tivity; Flavoprotein; Hydroxylation; Oxidoreduc-
tases
The selective oxyfunctionalisation of CH bonds
under mild reaction conditions is of great interest to
synthetic organic chemists. In recent years, much
effort has been put into developing metal-based
catalysts that can introduce oxygen atoms using
environmentally benign oxidants such as molecular
oxygen.[1,2] An attractive alternative to traditional
chemical catalysts is the use of enzymes capable of
introducing oxygen atoms, which often display exqui-
site regio- and enantioselectivity and are active under
mild reaction conditions. Well-known classes of oxy-
genating enzymes include heme-dependent cyto-
chrome P450 enzymes and peroxygenases, non-heme
iron oxygenases and flavin-dependent oxygenases.[3–7]
Some of these enzymes have been utilised to obtain
valuable products from preparative-scale transforma-
tions.[8–12] For many others, however, our knowledge of
their oxyfunctionalisation capabilities is limited to the
analytical scale. In order to stimulate the use of
oxidoreductases in industrial chemical synthesis, it is
crucial to demonstrate that they can be used to obtain
compounds on a synthetically relevant scale.[13]
Chiral alcohols, which are often important inter-
mediates in the synthesis of active pharmaceutical
ingredients, present an interesting target for these
preparative-scale transformations.[14] One class of alco-
hols that are important pharmaceutical building blocks
are chiral a-aryl alcohols.[15,16] A number of biocata-
lytic approaches for their synthesis have been de-
scribed, including enantioselective reduction of a
prochiral ketone, kinetic resolution or deracemisation
of racemic alcohols and the enantioselective hydration
of vinylphenol derivatives.[17–22] Another potential
enzymatic synthesis route for chiral a-aryl alcohols is
the direct oxyfunctionalisation of alkyl-substituted
aromatic molecules. An enzyme that can be used for
this purpose is vanillyl alcohol oxidase from Penicil-
lium simplicissimum (VAO, EC 1.1.3.38), which is
capable of catalysing the enantioselective hydroxyla-
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tion of 4-alkylphenols. Here, we describe the develop-
ment of the multigram scale enzymatic synthesis of
(R)-1-(4’-hydroxyphenyl)ethanol using VAO. This
compound may be of use for the synthesis of bioactive
molecules containing 1-(4’-hydroxyphenyl)ethanol
moieties. For example, racemic 1-(4’-hydroxyphenyl)
ethanol has been employed as an intermediate in the
synthesis of artemisinin derivatives that display immu-
nosuppressive activity, though the bioactive enantiom-
er was not defined.[23]
VAO catalyses the oxidation of a wide range of
para-substituted phenols at their Ca atom using
molecular oxygen as an electron acceptor.[24,25] VAO
displays a broad substrate scope, catalysing the
oxidation of benzylic alcohols or amines, the oxidative
demethylation of 4-(methoxymethyl)phenol and the
hydroxylation of 4-allylphenols. In addition, VAO
oxidises phenols bearing unfunctionalised alkyl chains
as the para-substituent. This leads to mixtures of
hydroxylated and dehydrogenated products, with the
ratio between the two being determined by the size of
the alkyl chain[26,27] and the composition of the
reaction medium.[28] The hydroxylation of short chain
4-alkylphenols proceeds with high regio- and enantio-
selectivity. The conversion of 4-ethylphenol, 4-propyl-
phenol or 2-methoxy-4-propylphenol by VAO yields
the corresponding 1-(4’-hydroxyphenyl)alcohols as the
sole hydroxylation product, in addition to more minor
amounts of vinylic side-products from dehydrogen-
ation of the substrate and ketone side-products from
further oxidation of the formed alcohols
(Scheme 1).[29] The hydroxylation reaction is highly
enantioselective, with the (R)-enantiomers of the
alcohol product being formed at 94% ee in all cases.
The catalytic mechanism of VAO provides an
explanation for this regio- and enantioselectivity.[30–32]
Binding of the phenolate form of the substrate to the
active site is followed by hydride transfer from the Ca
atom of the substrate to the N5 atom of the FAD
cofactor (Scheme 2). This yields a planar para-quinone
methide intermediate, which is subsequently hydrated
in the enzyme’s active site. The enantioselectivity of
the hydration is determined by the presence of an
active site base (Asp-170) that activates water for
attack at one side of the planar para-quinone methide
intermediate. Accumulation of the (R)-enantiomer is
further enhanced by the fact that the (S)-enantiomer
of 1-(4’-hydroxyphenyl)ethanol is more easily oxidised
further to 4-hydroxyacetophenone than the (R)-enan-
tiomer is.[26] AVAO variant (D170S/T457E) where the
active site base was moved to the other side of the
substrate displayed reversed enantioselectivity, con-
verting 4-ethylphenol to (S)-1-(4’-hydroxyphenyl)
ethanol at 80% ee.[33] Its ability to catalyse regio- and
enantioselective hydroxylations using only molecular
oxygen as a cosubstrate makes VAO an interesting
candidate for biocatalytic applications.
The synthetic utility of VAO at small scale has
been demonstrated previously. The conversion of 4-
ethylphenol and 2-methoxy-4-propylphenol was per-
Scheme 1. Conversion of 4-ethylphenol (1) by VAO. Thick-
ness of the arrows gives a qualitative indication of the
relative rates at which the depicted reactions occur. VAO
readily converts 4-ethylphenol to (R)-1-(4’-hydroxyphenyl)
ethanol (2), with (S)-1-(4’-hydroxyphenyl)ethanol (3) and 4-
vinylphenol (4) being formed as side-products. The formed
alcohol can subsequently be oxidised further to 4-hydroxy-
acetophenone (5), with the (S)-enantiomer being more
readily converted than the (R)-enantiomer. Scheme adapted
from.[26]
Scheme 2.Mechanism of the enantioselective hydroxylation
of 4-ethylphenol by VAO. First, 4-ethylphenol binds in the
enzymes active site in its phenolate form. Following this, a
hydride is transferred from the Ca atom of its ethyl group to
the N5 atom of FAD, yielding a para-quinone methide
intermediate and reduced FAD. Subsequently, a water
molecule is activated by Asp-170 and attacks the Ca atom of
the para-quinone methide intermediate, yielding the alcohol
product. Stopped-flow kinetics analysis has demonstrated
that this occurs after (or possibly concomitant to) the
reoxidation of FAD by molecular oxygen.[31] The position of
Asp-170 relative to the planar para-quinone methide inter-
mediate explains the preferential formation of the (R)-
enantiomer of 1-(4’-hydroxyphenyl)ethanol.
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formed at 100 mg scale, yielding 33.2 mg (28%) and
52 mg (45%) respectively of the corresponding puri-
fied alcohols.[29] To evaluate the potential of VAO to
be used as a biocatalyst for the synthesis of chiral
alcohols on a more synthetically relevant scale, we
scaled up the conversion of 4-ethylphenol to the 10 g
scale.
As a first step in the scale-up process, we optimised
the reaction conditions for the conversion of 4-ethyl-
phenol (1) at an analytical scale by testing the effect
of the addition of organic solvents to the reaction
medium. To this end, the conversion of 5 mg 1 was
performed in 84 mM potassium phosphate buffer,
pH 7.5, in the presence of 10% acetone or acetonitrile.
The composition of reaction mixtures after the reac-
tion as determined by gas chromatography is given in
Table 1. Using acetone as a cosolvent gave the best
results, with complete conversion of 1 and 83% of the
formed product being (R)-1-(4’-hydroxyphenyl)
ethanol (2) after 4 h. The formation of 2 is under-
estimated, as part of the 1-(4’-hydroxyphenyl)ethanol
undergoes elimination of water during the gas chro-
matographic analysis, yielding 4-vinylphenol (4) [as
confirmed by GC analysis of racemic pure 1-(4’-
hydroxyphenyl)ethanol]. The addition of acetone
likely improves the solubility of the aromatic substrate
and products. In addition, the solubility of oxygen in
acetone is increased as compared to in water [277 mg/
L in acetone at 25 8C and 44 mg/L in water at 20 8C at
1 bar pure oxygen atmosphere[34]], preventing oxygen
depletion from becoming limiting for the reaction.
Although the solubility of the substrates may be
increased further by using even higher concentrations
of acetone, its presence led to significant inhibition of
the enzyme. The rate of conversion of 2 mM vanillyl
alcohol to vanillin by VAO in 50 mM potassium
phosphate buffer, pH 7.5, at 25 8C dropped from
2.2 s1 in the absence of acetone to 0.73 s1 in the
presence of 10% acetone and 0.12 s1 in the presence
of 20% acetone. With this in mind, scale-up was
performed using the reaction medium containing 10%
acetone.
Scaling up the reaction to 100 mg scale with
increased substrate concentrations revealed that al-
most complete conversion (97%) could be achieved
using a substrate concentration of 23 mM and 2 U
VAO (Table 2, reaction a). Increasing the substrate
concentration further to 45 mM led to lower conver-
sion (87%) even though the same enzyme to substrate
ratio was used (Table 2, reaction b). Therefore, 23 mM
Table 1. Products obtained from the conversion of 4-ethyl-
phenol (1) by VAO in the presence of organic solvents. 5 mg
1 (at a concentration of 2.9 mM) and 0.4 U VAO were
incubated in 84 mM potassium phosphate buffer, pH 7.5, at
30 8C in the presence of 10% acetone or 10% acetonitrile.
After the incubation period, reaction products were ex-
tracted and analysed by GC. Compounds are numbered as in
Scheme 1. GC chromatograms are shown in Figure S1. The
given numbers are the amount of a compound as a
percentage of the total present upon analysis.
Reaction
conditions
1
(%)
2
(%)
3
(%)
2-ee
(%)
4
(%)
5
(%)
10% acetone, 4 h – 83 0.7 98 14 3.0
10% acetonitrile, 22 h 5.9 76 2.5 94 14 1.3
Table 2. Products obtained from the conversion of 4-ethylphenol (1) by VAO. 1 and VAO or His-VAO cell-free extract were
incubated in 88 mM potassium phosphate buffer, pH 7.5, containing 10% acetone at 30 8C for 24 h. Subsequently, reaction
products were extracted and analysed by GC or 1H-NMR. Compounds are numbered as in Scheme 1. GC chromatograms are
shown in Figure S2, 1H-NMR spectra in Figure S4. The given numbers are the amount of a compound as a percentage of the
total present upon analysis. CFE: cell-free extract.
Reaction Substrate Enzyme 1
(%)
2
(%)
3
(%)
2+3
(%)
2-ee
(%)
4
(%)
5
(%)
a GC 100 mg
23 mM
2 U VAO 3.1 83 4.0 91 8.3 1.5
b GC 100 mg
45 mM
2 U VAO 13 58 4.1 87 24 1.0
c GC 100 mg
23 mM
2 U His-VAO CFE 0.8 74 2.1 95 23 0.9
d GC 1.0 g
23 mM
20 U His-VAO CFE 6.5 83 1.3 97 8.6 0.8
1H-NMR 7.5 88 2.6 1.8
e GC 13.4 g
23 mM
268 U His-VAO CFE 37 51 1.9 93 9.2 1.1
f[a] GC 10.0 g
23 mM
202 U His-VAO CFE 6.0 82 4.1 90 6.5 1.0
1H-NMR 6.3 89 2.7 1.8
[a] Reaction vessel was kept under pure O2 atmosphere for the first 9 h.
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substrate with 0.02 U VAO/mg substrate was chosen
as the conditions for scale-up.
As the costs associated with protein purification
could be a major hurdle for the use of enzymatic
conversions in an industrial setting, we subsequently
tested whether we could eliminate this step by
performing the reaction using a cell-free extract of
Escherichia coli expressing an N-terminally His-tagged
variant of VAO. The plasmid encoding for this His-
tagged VAO, pJ404-His-VAO, contains a version of
the gene encoding for VAO that is codon-optimised
for expression in E. coli. This construct allows VAO to
be expressed at higher levels than the previously used
plasmid, pBC11,[35] which contains the vaoA gene
from P. simplicissimum. Using this cell-free extract,
the conversion of 100 mg 1 gave a similar result to
that using the purified enzyme (Table 2, reaction c).
Apparently, the use of E. coli cell-free extract did not
lead to any undesired side reactions taking place.
Therefore, the cell-free extract was used for further
scale-up reactions.
Having established the optimised reaction condi-
tions for the conversion of 1 to 2, we next set out to
scale up the reaction to a more synthetically relevant
scale of 10 g of substrate. First, the reaction was scaled
up to 1 g of substrate using the same reaction
conditions as for 100 mg. This led to almost complete
conversion (93%) of 1 and to similar formation of 2 as
was obtained at 100 mg scale (Table 2, reaction d).
Analysis of the reaction products by 1H-NMR allowed
quantification of the products without being hindered
by the decomposition of 1-(4’-hydroxyphenyl)ethanol
to 4 observed during GC analysis, revealing that the
enzymatic reaction yields less than 3% of 4 as a side-
product (Table 2, reaction d). To obtain pure 2, it was
purified from the crude reaction mixture by recrystal-
lisation, yielding 244.3 mg (21%) pure 2 at 99% ee
(Figures S3+S4).
Subsequently, the reaction was scaled up to our
final target scale of approximately 10 g of starting
material. However, using the same reaction conditions
with 13.4 g 1 led to lower conversion of the substrate
[63% (Table 2, reaction e)]. TLC analysis revealed
that the reaction was essentially complete after 9 h,
with no further product formation being observed
after this time. Possibly, the reaction does not proceed
further due to inactivation of the enzyme. As the large
volume used for this reaction could lead to oxygen
depletion becoming rate-limiting, we performed the
reaction with 10 g 1 under identical conditions, but
with the reaction vessel under oxygen atmosphere for
the first 9 h of the reaction to try and increase the
conversion of the substrate. Under these conditions,
the substrate was almost completely converted after
24 h [94% (Table 2, reaction f)]. TLC analysis again
revealed that the reaction was essentially complete
after 9 h under oxygen atmosphere. Extraction of the
reaction mixture with ethyl acetate yielded 6.51 g
crude product. Based on the 82% formation of 2
observed in the GC experiments, a crude yield of
5.34 g (47%) 2 can be estimated. After recrystallisa-
tion, pure 2 was obtained in 36% isolated yield and
97% ee (Figures S3+S4). The observation that main-
taining sufficient oxygen levels is crucial to allow the
reaction to proceed is in agreement with previous
studies regarding biotransformations using monooxy-
genase-containing whole-cell biocatalysts, where oxy-
gen depletion was found to be limiting for the reaction
under certain conditions.[8, 36,37] Although we were able
to maintain sufficient oxygen levels by performing the
reaction under an oxygen atmosphere, this may not be
suitable for an industrial-scale reaction as the use of
pure oxygen poses an explosion hazard. Use of
alternative systems to achieve sufficient oxygen levels,
such as bubble aeration could provide a solution for
industrial-scale transformations.[38] One aspect of the
process that can be improved upon is the fact that,
despite observing 82% formation of 2 in the largest-
scale reaction, the isolated yield is relatively low at
36%. This low yield is attributable to significant losses
of material during both the extraction of the product
from the reaction mixture (6.51 g crude product
obtained from 10 g starting material) and during
recrystallisation. The loss of material during the
extraction procedure may be attributable to the
relatively high polarity of the product making its
extraction into organic solvents inefficient. This may
be solved in future by testing other solvents for
extraction or by performing more rounds of extrac-
tion. From the GC data, it can be calculated that the
crude compound obtained after extraction contains
5.34 g 2, which corresponds to a crude yield of 47%.
This means that a further 23% of the product was lost
during its purification by recrystallisation. Although
this loss is significant, recrystallisation is likely the
most efficient method to increase the ee of the product
by removing the (S)-1-(4’-hydroxyphenyl)ethanol
formed as a side-product.
1-(4’-Hydroxyphenyl)ethanol can also be biocata-
lytically synthesised by the hydration of 4-vinylphenol
using phenolic acid decarboxylase (PAD).[20,22] All
tested PADs preferentially yielded the (S)-enantiomer
of 1-(4’-hydroxyphenyl)ethanol, providing a potential
route to the opposite enantiomer than that formed by
VAO.
Here, we described the scale-up of the synthesis of
(R)-1-(4’-hydroxyphenyl)ethanol by the enantioselec-
tive hydroxylation of 4-ethylphenol by VAO. Under
optimised reaction conditions, 94% conversion of 10 g
4-ethylphenol was obtained after 24 h. Purification of
the product yielded (R)-1-(4’-hydroxyphenyl)ethanol
in 36% isolated yield and 97% ee. These results
highlight some of the issues that may be encountered
during scale-up of an enzymatic hydroxylation reac-
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tion from analytical scale to a synthetically relevant
scale and may be of use in facilitating such scale-up
for the synthesis of chiral pharmaceutical intermedi-
ates in an industrial setting.
Experimental Section
Materials
4-Ethylphenol and 4-hydroxyacetophenone were from abcr
(Karlsruhe, Germany). An analytical standard for 1-(4’-
hydroxyphenyl)ethanol was synthesised as a racemic mixture
from 4-hydroxyacetophenone:
A solution of 4-hydroxyacetophenone (3.4 g, 25 mmol) in
MeOH (50 mL) was stirred at 15–20 8C and a solution of
NaBH4 (0.57 g, 15 mmol) in 0.2 M aqueous NaOH (10 mL)
was added. Subsequently, the reaction mixture was stirred at
room temperature for 20 h. After this, MeOH was removed
by evaporation and water (10 mL) was added to the residue.
The mixture was extracted with CHCl3/isopropanol (3/1) and
the organic layer was dried over Na2SO4 and the solvent was
removed by evaporation. The residue (2.2 g, yellow solid)
was chromatographed on silica gel with dichloromethane/
MeOH (50/1), yielding pure (R,S)-1-(4’-hydroxyphenyl)
ethanol (1.45 g, white solid, 42%). The elution times of the
enantiomers upon gas chromatography analysis were as-
signed by comparison with 1-(4’-hydroxyphenyl)ethanol
formed by conversion of 1 by VAO [primarily (R)-enantiom-
er].
1H-NMR (d6-DMSO, 400 MHz): d (ppm): 9.10 (s, 1H, Ar-
OH), 7.12 (dt, J=8.02 Hz, 2H, ArH), 6.68 (dt, J=8.69 Hz,
2H, ArH), 4.85 (d, J=4.29 Hz, 1H, aliph.-OH), 4.63-4.57
(m, 1H, CH), 1.27 (d, J=6.44 Hz, 3H, CH3).
All other chemicals were from commercial sources and of
the purest grade available.
Expression and Purification of VAO
For small-scale tests with purified enzyme, VAO was ex-
pressed and purified as described previously.[39] For larger-
scale reactions using cell-free extracts, N-terminally His-
tagged VAO was expressed from the pJ404-His-VAO
plasmid, which contains a version of the vaoA gene from P.
simplicissimum that is codon-optimised for expression in E.
coli behind an IPTG-inducible T5 promoter. BL21 E. coli
cells containing this plasmid were grown at 37 8C in LB
medium containing 100 mg/mL ampicillin until the OD600 of
the cultures was 0.6. Subsequently, IPTG was added to a
concentration of 0.8 mM and the cells were grown overnight
at 25 8C. Following this, cells were harvested by centrifuga-
tion (4,000 g, 10 min, 10 8C), resuspended in 50 mM potassi-
um phosphate buffer, pH 7.0, containing 0.5 mM dithiothrei-
tol, 0.5 mM MgSO4 and one cOmplete
TM protease inhibitor
pill (Roche, Basel, Switserland) and 1 mg DnaseI (Roche)
per 50 mL, and lysed by passing them through a pre-cooled
SLM Aminco French Pressure Cell three times. Subse-
quently, cell debris was removed by centrifugation (39,000 g,
45 min, 4 8C) and the obtained soluble fractions were used
for the reactions.
VAO activity was determined by monitoring the conversion
of vanillyl alcohol (4-hydroxy-3-methoxybenzyl alcohol) to
vanillin (4-hydroxy-3-methoxybenzaldehyde) at 25 8C in
50 mM potassium phosphate buffer, pH 7.5, by measuring
the absorption of the product at 340 nm (e=
14,000 M1 cm1[24]) using a Hewlett Packard 8453 diode array
spectrophotometer (Agilent Technologies, Santa Clara, CA,
USA).
Gas Chromatography
Gas chromatography experiments were performed on a GC-
2010 plus (Shimadzu, Kyoto, Japan) with an FID detector
(260 8C) and a Hydrodex b-6TBDM column (25 m3
2.45 mm, Machery-Nagel, Du¨ren, Germany). Hydrogen was
used as a carrier gas at a flow rate of 1.5 mL/min and the
injector temperature was 80 8C. Runs were performed using
a 20 min gradient from 80 to 220 8C followed by 10 min at
220 8C.
Analytical-Scale Conversions of 4-Ethylphenol
1 (5 mg, 41 mmol), VAO (0.4 U, 0.8 mL of a 0.5 U/mL
solution in 50 mM potassium phosphate buffer, pH 7.5) the
specified organic solvent (1.4 mL) and 100 mM potassium
phosphate buffer, pH 7.5, (11.8 mL) were incubated at 30 8C.
The reaction was performed in a 25 mL flask that was open
to air and the reaction mixture was stirred using a magnetic
stirrer. The stirrer speed was adjusted so as to form a
whirlpool in the solution to achieve maximal aeration. After
the reaction, the solution was concentrated under reduced
pressure. The residue was extracted with EtOAc (435 mL).
The organic layer was dried over Na2SO4 and filtered, and
the solvent was removed by evaporation. The residue was
dissolved in MeOH (1 mL) and analysed by GC.
Scale-up to the 100 mg scale was performed using the same
procedure, but with the volume of the reaction mixture
adapted to achieve the desired substrate concentration and
using 2 U VAO (or His-VAO cell-free extract). Reactions
were performed in 100 mL flasks that were open to air.
Synthesis of (R)-1-(4’-Hydroxyphenyl)ethanol at 1g
Scale
1 (1 g, 8.2 mmol) was dissolved in acetone (34.5 mL).
100 mM potassium phosphate buffer, pH 7.5, (296 mL) and
His-VAO cell-free extract (20 U, 14.3 mL of a 1.4 U/mL
solution) were added to the solution. Reactions were
performed in a 1 L flask that was open to air and the reaction
mixture was stirred using a magnetic stirrer. The stirrer speed
was adjusted so as to form a whirlpool in the solution to
achieve maximal aeration. The reaction solution was stirred
for 24 h at 30 8C (water bath) under air atmosphere. After
24 h, the solution was concentrated under reduced pressure
at 50 8C (water bath). During concentration, a slimy white
solid was formed. The suspension was filtered and the
aqueous phase was extracted with EtOAc. The organic phase
was washed with brine, dried over Na2SO4 and concentrated
under reduced pressure to give a crude compound (502 mg,
green beige solid). This compound was analysed by GC and
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1H-NMR to evaluate the success of the conversion. Sub-
sequently, the crude product was purified by recrystallisation.
EtOAc (3 mL) was added to the crude product and the
suspension was heated to 80 8C (oil bath) until all solid was
dissolved. Subsequently, the solution was cooled to room
temperature, during which a solid crystallised. The solid was
filtered and washed with a hexane/EtOAc mixture (1/1). The
solid was dried under reduced pressure at 50 8C (water bath)
to give the product (244.3 mg, white solid, 22%).
Synthesis of (R)-1-(4’-Hydroxyphenyl)ethanol at 10g
Scale
1 (10 g, 82 mmol) was dissolved in acetone (345 mL).
100 mM potassium phosphate buffer, pH 7.5, (3075 mL) and
His-VAO cell-free extract (202 U, 31 mL of a 6.5 U/mL
solution) were added to the solution. The reaction was
performed in a 4 L flask and the solution was stirred with an
overhead stirrer (230 rpm). The reaction vessel was evac-
uated and then brought under O2 atmosphere using a balloon
filled with O2 gas. The solution was stirred for 9 h under O2
atmosphere and, subsequently, 15 h under air atmosphere at
30 8C (water bath). After 24 h, the solution was concentrated
under reduced pressure at 50 8C (water bath). During
concentration, a slimy white solid was formed. The suspen-
sion was filtered and the aqueous phase (1 L) was
extracted with EtOAc (131 L, then 33500 mL). The organic
phase was washed with brine, dried over Na2SO4 and
concentrated under reduced pressure to give a crude
compound (6.51 g, green beige solid). This compound was
analysed by GC and 1H-NMR to evaluate the success of the
conversion. Subsequently, the crude product was purified by
recrystallisation. EtOAc (38 mL) was added to the crude
compound and the suspension was heated to 90 8C (oil bath)
until all solid was dissolved. Subsequently, the solution was
cooled to room temperature, during which a solid crystal-
lised. The solid was filtered and washed with a hexane/
EtOAc mixture (1/1). The solid was dried under reduced
pressure at 50 8C (water bath) to give the product (4.10 g,
white solid, 36%).
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